Revelation Biosciences Q2 2023 net loss $1.4M; cash $15.7M; 6-month net income $4.7M on warrant gain

REVELATION BIOSCIENCES, INC.

2023-Q2 EPS reported $1.53

Cash and cash equivalents of $15.7M as of June 30, 2023, up from $5.3M at Dec 31, 2022.
Net loss for Q2 2023 was $1.4M ($0.25 per share) vs $1.8M ($4.16 per share) in Q2 2022.
Net income for 6 months ended June 30, 2023 was $4.7M ($1.61 basic EPS) vs net loss of $8.5M in prior period, driven by $8.2M warrant liability gain.
Net cash used for operating activities for 6 months ended June 30, 2023 was $3.6M, down from $8.5M year-over-year.
Management believes current cash sufficient to fund operations through June 2024; decreased clinical study expenses contributed to lower losses.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

REVELATION BIOSCIENCES, INC. reported the three and six months ended June 30, 2023 results: net income net loss of $1.4 million, or $0.25 basic and diluted net loss per share, EPS $0.25 basic and diluted net loss per share.

Period: the three and six months ended June 30, 2023
Net income: net loss of $1.4 million, or $0.25 basic and diluted net loss per share
EPS: $0.25 basic and diluted net loss per share
Result: reported results

Exact text from the filing

On August 11, 2023, Revelation Biosciences, Inc. issued a press release announcing its financial results for the three and six months ended June 30, 2023.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

REVELATION BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0000950170-23-041889

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.